Olivier Nicolas Kocher, Ph.D., M.D.
This page shows the publications co-authored by Olivier Kocher and Daniel Tenen.
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer. EMBO Mol Med. 2018 03; 10(3).
In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood. 2013 Feb 21; 121(8):1255-64.
Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in mice. Mol Cell Biol. 2006 Feb; 26(3):1109-23.
Down-regulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res. 2002 Jan 15; 62(2):528-34.
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. Commun Biol. 2021 04 14; 4(1):370.
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPa expression. Sci Transl Med. 2016 08 03; 8(350):350ra104.
Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer. 2012 Jul; 77(1):31-7.
CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells. Development. 2010 Jul; 137(13):2147-56.
Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. Lung Cancer. 2007 Apr; 56(1):97-103.
Three-dimensional magnetic resonance microscopy of pulmonary solitary tumors in transgenic mice. Magn Reson Med. 2006 Sep; 56(3):698-703.
C/EBPa expression by immunohistochemistry lacks prognostic or predictive significance in primary resected non-small cell lung cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7202.
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24; 352(8):786-92.
Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. J Clin Oncol. 2005 Jan 01; 23(1):235-7.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.